Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
Affected Genes

Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Ratio Regulation description Class Gene Ontology Gene Accession Minimum Ratio Maximum Ratio
Results: HTML CSV LaTeX
Showing element 1 to 39 of 39 in total
Class: molecular function
Gene Ontology: metal ion binding

\def\wcA{0.25\textwidth}
\def\wcB{0.25\textwidth}
\def\wcC{0.25\textwidth}
\begin{longtable}{|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Ratio\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Regulation\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.07618\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit- related protein 2 (U2(RNU2) small nuclear RNA auxiliary factor 1-like 2) (CCCH type zinc finger, RNA-binding motif and serine/arginine rich protein 2) (Renal carcinoma antigen NY-REN-20). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.1243\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Zinc finger protein basonuclin-2. \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.13007\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Zinc finger protein 219. \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.18096\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Prostaglandin G/H synthase 2 precursor (EC 1.14.99.1) (Cyclooxygenase- 2) (COX-2) (Prostaglandin-endoperoxide synthase 2) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.18489\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Guanylate cyclase soluble subunit beta-2 (EC 4.6.1.2) (GCS-beta-2). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.20102\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Metalloreductase STEAP3 (EC 1.16.1.-) (Six-transmembrane epithelial antigen of prostate 3) (Tumor suppressor-activated pathway protein 6) (hTSAP6) (pHyde) (hpHyde) (Dudulin-2). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.22576\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Methyl-CpG-binding domain protein 1 (Methyl-CpG-binding protein MBD1) (Protein containing methyl-CpG-binding domain 1). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.23783\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Centaurin-delta 1 (Cnt-d1) (Arf-GAP, Rho-GAP, ankyrin repeat and pleckstrin homology domain-containing protein 2) (PARX protein). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.25113\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Zinc finger protein OZF (Only zinc finger protein) (Zinc finger protein 146). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.28805\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
ADAM metallopeptidase with thrombospondin type 1 motif, 7 preproprotein \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.30869\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
E3 ubiquitin-protein ligase CHFR (EC 6.3.2.-) (Checkpoint with forkhead and RING finger domains protein) (RING finger protein 196). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.31489\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Tripartite motif-containing protein 58 (Protein BIA2). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.37411\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Lariat debranching enzyme (EC 3.1.-.-). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.42264\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
RNA-binding protein 4 (RNA-binding motif protein 4) (RNA-binding motif protein 4a) (Lark homolog) (hLark). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.43351\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Carboxypeptidase A2 precursor (EC 3.4.17.15). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.48389\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Nuclear pore complex protein Nup153 (Nucleoporin Nup153) (153 kDa nucleoporin). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.49264\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Cytochrome P450 2W1 (EC 1.14.14.-) (CYPIIW1). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.56335\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Zinc finger SWIM domain-containing protein 3. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.57088\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Forkhead box protein P2 (CAG repeat protein 44) (Trinucleotide repeat- containing gene 10 protein). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.59188\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Zinc finger protein 384 (Nuclear matrix transcription factor 4) (Nuclear matrix protein 4) (CAG repeat protein 1) (CAS-interacting zinc finger protein) (Trinucleotide repeat-containing gene 1 protein). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.66679\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
TCDD-inducible poly [ADP-ribose] polymerase (EC 2.4.2.30) (Poly [ADP- ribose] polymerase 7) (PARP-7). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.76994\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ADAM 12 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase domain 12) (Meltrin alpha). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.78439\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Chromodomain helicase-DNA-binding protein 4 (EC 3.6.1.-) (ATP- dependent helicase CHD4) (CHD-4) (Mi-2 autoantigen 218 kDa protein) (Mi2-beta). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.86204\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Zinc finger and SCAN domain-containing protein 4 (Zinc finger protein 494). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.89168\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Zinc finger protein 202 (Zinc finger protein with KRAB and SCAN domains 10). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.93995\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Zinc finger protein ubi-d4 (Requiem) (Apoptosis response zinc finger protein) (D4, zinc and double PHD fingers family 2). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.98137\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Nuclear receptor ROR-alpha (Retinoid-related orphan receptor-alpha) (Nuclear receptor RZR-alpha). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2.31699\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform (EC 3.1.3.16) (PP2A-beta). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2.45875\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ADAMTS-19 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase with thrombospondin motifs 19) (ADAM-TS 19) (ADAM-TS19). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2.58329\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Myelin transcription factor 1-like protein (MyT1L protein) (MyT1-L). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2.69364\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Cytochrome P450 26A1 (EC 1.14.-.-) (Retinoic acid-metabolizing cytochrome) (P450 retinoic acid-inactivating 1) (P450RAI) (hP450RAI) (Retinoic acid 4-hydroxylase). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2.93895\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
TRAF family member-associated NF-kappa-B activator (TRAF-interacting protein) (I-TRAF). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
3.29064\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Transcription factor GATA-6 (GATA-binding factor 6). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
4.14054\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Protein odd-skipped-related 2. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
4.40598\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
GMP reductase 1 (EC 1.7.1.7) (Guanosine 5'-monophosphate oxidoreductase 1) (Guanosine monophosphate reductase 1). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
4.87049\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
zinc finger, FYVE domain containing 26 \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
5.61927\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
RING finger protein 170 (Putative LAG1-interacting protein). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
5.81102\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
PDZ and LIM domain protein 2 (PDZ-LIM protein mystique) (PDZ-LIM protein). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
6.3909\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Protein Jade-1 (PHD finger protein 17). \vspace{3pt}}\\\hline
nd{longtable}

Legend:
- The Ratio specifies how much this gene is up/down regulated. When up- or down-regulated must this value respectively be multiplied/divided to obtain the MK5 on concentration based on the MK5 off concentration.

 - The Regulation specifies how this gene is affected when going from the MK5 off cells to the MK5 on cells. 

 - The Class refers to the ontology category, which can be molecular_function, biological_process or cellular_component. 

 - The Gene Ontology terms as linked to the specific gene.

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Accession is the GO accession key. 

 - Minimum Ratio is the lowest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.

 - Maximum Ratio is the highest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.
- http://analysis.yellowcouch.org/